Clinical data
Other namesSL 81-0385; IXA-001
ATC code
  • None
  • 4-(naphthalen-2-ylmethoxy)piperidine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass241.334 g·mol−1
3D model (JSmol)
  • C3CNCCC3OCc2cc1ccccc1cc2

Litoxetine (developmental code names SL 81-0385, IXA-001) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s but was never marketed.[1][2] It acts as a potent serotonin reuptake inhibitor (Ki for SERT = 7 nM) and modest 5-HT3 receptor antagonist (Ki = 315 nM).[3][4] It has antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting.[5] The drug is structurally related to indalpine.[4] Development of litoxetine for depression was apparently ceased in the late 1990s.[6] However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the phase II stage for the treatment of urinary incontinence.[6]


  1. ^ "Litoxetine - AdisInsight". Retrieved 2018-08-25.
  2. ^ Fairweather DB, Patat A, Rosenzweig P, Curson VH, Dunmore C, Dubruc C, Hindmarch I (August 1995). "The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers". British Journal of Clinical Pharmacology. 40 (2): 119–25. doi:10.1111/j.1365-2125.1995.tb05767.x. PMC 1365170. PMID 8562293.
  3. ^ Zoran Rankovic; Richard Hargreaves; Matilda Bingham (8 October 2012). Drug Discovery for Psychiatric Disorders. Royal Society of Chemistry. pp. 195–. ISBN 978-1-84973-494-3.
  4. ^ a b Progress in Drug Research. Birkhäuser. 6 December 2012. pp. 80–. ISBN 978-3-0348-8391-7.
  5. ^ Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ (March 1993). "Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties". European Journal of Pharmacology. 232 (2–3): 139–45. doi:10.1016/0014-2999(93)90767-C. PMID 8385615.
  6. ^ a b "Litoxetine - IXALTIS - AdisInsight".